Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Corvus Pharmaceuticals (CRVS) Operating Income (2016 - 2026)

Corvus Pharmaceuticals' Operating Income history spans 12 years, with the latest figure at -$14.9 million for Q1 2026.

  • Quarterly Operating Income fell 49.94% to -$14.9 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$47.9 million through Mar 2026, down 53.53% year-over-year, with the annual reading at -$43.0 million for FY2025, 55.99% down from the prior year.
  • Operating Income came in at -$14.9 million for Q1 2026, down from -$12.2 million in the prior quarter.
  • In the past five years, Operating Income ranged from a high of -$5.6 million in Q3 2023 to a low of -$14.9 million in Q1 2026.
  • The 5-year median for Operating Income is -$7.3 million (2024), against an average of -$8.3 million.
  • Year-over-year, Operating Income surged 55.42% in 2023 and then plummeted 72.87% in 2025.
  • Corvus Pharmaceuticals' Operating Income stood at -$5.7 million in 2022, then rose by 0.26% to -$5.7 million in 2023, then crashed by 43.43% to -$8.1 million in 2024, then plummeted by 50.73% to -$12.2 million in 2025, then dropped by 21.77% to -$14.9 million in 2026.
  • Per Business Quant, the three most recent readings for CRVS's Operating Income are -$14.9 million (Q1 2026), -$12.2 million (Q4 2025), and -$10.6 million (Q3 2025).